帕妥珠单抗 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "帕妥珠单抗" in Chinese language version.

refsWebsite

Global rank Chinese rank

1^st place

4^th place

5^th place

low place

6^th place

4^th place

2^nd place

23^rd place

low place

adisonline.com (Global: low place; Chinese: low place)

Keating GM. Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. Drugs 2012 Feb 12; 72 (3): 353-60.Link text^{[永久失效連結]}

de Bono, Johann S.; Bellmunt, J; Attard, G; Droz, JP; Miller, K; Flechon, A; Sternberg, C; Parker, C; Zugmaier, G. Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer. Journal of Clinical Oncology. 20 January 2007, 25 (3): 257–262. PMID 17235043. doi:10.1200/JCO.2006.07.0888.
Baselga J, Cortés J, Kim SB, and the CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012 Jan 12; 366 (2): 109-19. Link text （页面存档备份，存于互联网档案馆）

FDA Approves Perjeta (Pertuzumab) for People With HER2-Positive Metastatic Breast Cancer (新闻稿). Genentech. [2012-06-09]. （原始内容存档于2012-12-09）.
Genentech press release （页面存档备份，存于互联网档案馆） - May 15, 2005
Baselga J, Cortés J, Kim SB, and the CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012 Jan 12; 366 (2): 109-19. Link text （页面存档备份，存于互联网档案馆）